Related Experiment Video
Updated: Aug 15, 2026
08:49
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Pyrrolopyridazine MEK inhibitors
Zhong Chen1, Soong-Hoon Kim, Stephanie A Barbosa
1Bristol-Myers Squibb, Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543-4000, USA. zhong.chen@bms.com
Bioorganic & Medicinal Chemistry Letters
|November 9, 2005
Summary
Researchers synthesized novel pyrrolopyridazine compounds as MEK inhibitors. The most effective compounds featured a 4-phenoxyaniline group and an acylated amine for optimal biological activity.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Pharmacology
Background:
- Mitogen-activated protein kinase kinase (MEK) is a key regulator in cellular signaling pathways.
- Dysregulation of MEK signaling is implicated in various diseases, including cancer.
- Developing potent and selective MEK inhibitors is a significant therapeutic goal.
Purpose of the Study:
- To synthesize and characterize a novel series of pyrrolopyridazine derivatives.
- To investigate the structure-activity relationships (SAR) of these compounds as MEK inhibitors.
- To identify optimal structural features for enhanced MEK inhibitory activity.
Main Methods:
- Multi-step organic synthesis was employed to generate the pyrrolopyridazine core structure.
- Systematic modification of substituents at various positions (C4 and C6) was performed.
- Biological assays were conducted to evaluate the inhibitory potency against MEK.
Main Results:
- A series of pyrrolopyridazine compounds were successfully synthesized.
- Structure-activity relationship studies revealed key determinants of MEK inhibition.
- Optimal activity was achieved with the incorporation of a 4-phenoxyaniline substituent at the C4 position.
- Further optimization involved the addition of an acylated amine moiety at the C6 position, leading to enhanced potency.
Conclusions:
- The synthesized pyrrolopyridazine derivatives represent a promising class of MEK inhibitors.
- The 4-phenoxyaniline at C4 and acylated amine at C6 are crucial for potent MEK inhibition.
- These findings provide a foundation for the development of new therapeutics targeting MEK-driven diseases.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...